Acadia Healthcare (NASDAQ: ACHC) reported Q2 EPS of $0.66, $0.01 better than the analyst estimate of $0.65. Revenue for the quarter came in at $715.9 million versus the consensus estimate of $716.7 million.

“Our growth in same facility revenue for the second quarter resulted, in part, from the addition of 625 new beds to existing facilities in the 12 months ended June 30, 2017. During the second quarter, 91 new beds were added to existing facilities, and we expect to add approximately 800 new beds to existing facilities and three de novo facilities in 2017.”

For the second quarter of 2017, Acadia’s total same facility EBITDA margin was 26.4% compared with 26.7% for the second quarter of 2016. Acadia’s consolidated adjusted EBITDA was $162.2 million, or 22.7% of revenue, for the second quarter of 2017, compared with $172.2 million or 22.8% of revenuefor the second quarter of 2016.

Acadia today adjusted its financial guidance for 2017 within the previously established ranges, as follows:

• Revenue for 2017 in a range of $2.85 billion to $2.87 billion;
• Adjusted EBITDA for 2017 in a range of $628 million to $635 million; and
• Adjusted earnings per diluted share for 2017 in a range $2.42 to $2.47.

GUIDANCE:

Acadia Healthcare sees FY2017 EPS of $2.42-$2.47. Acadia Healthcare sees FY2017 revenue of $2.85-2.87 billion.

For earnings history and earnings-related data on Acadia Healthcare (ACHC) click here.